Navigation Links
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Date:6/11/2008

SEATTLE and PARIS, June 12 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists. Full results of the study were presented here today during an oral presentation at the Annual European Congress of Rheumatology (EULAR).

The Phase 1/2 study evaluated multiple doses of tgAAC94 administered directly to affected joints with or without concurrent systemic TNF antagonist therapies. The study achieved its primary endpoint of safety and tolerability.

"We are encouraged by the patient-reported symptom improvement -- early signs of efficacy that indicate further study is warranted," said Philip Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, who presented the data.

Study Details

127 patients with inflammatory arthritis received a single intra-articular injection of either tgAAC94 or placebo, followed by a second injection 12-30 weeks later depending on when the injected joint met criteria for re-injection. tgAAC94 was well tolerated at all dose levels. Two SAEs of focused interest were reported -- a culture-negative septic arthritis considered probably related to study drug and a fatal disseminated histoplasmosis and retroperitoneal hemorrhage considered not related to study agent. Administration site reactions were observed in 12% of subjects.
'/>"/>

SOURCE Targeted Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
2. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
3. Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
4. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
5. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
6. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
9. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
10. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TEANECK, N.J. , May 21, 2013 /PRNewswire-iReach/ ... 17-19 in NJ has attracted the greatest number ... reports its President, Mark Alexay ... "But suddenly everyone plans to attend this year.  The show,s still ... of different companies.  This is a big surprise ...
(Date:5/21/2013)... 2013  IsoRay, Inc. (AMEX: ISR ), ... into an exclusive international distribution agreement with IASIS Medical ... Greece . IsoRay is a medical ... radioisotope applications for brain cancer, lung cancer, head and ... IASIS Medical is ideally suited to support ...
(Date:5/21/2013)... 2013  The North Shore-LIJ Health System is expanding ... compliance at North Shore University Hospital in ... rooms at Forest Hills (NY) ... The new pilot program strengthens patient safety by providing ... the first time in the US that remote video ...
Breaking Medicine Technology:Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4
(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, ... of victims injured by defective medical devices, is addressing ... Joint Surgery on May 15, 2013. The study found ... identify complications that occur in patients with metal-on-metal hip ... ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , “We’ve known ...
(Date:5/21/2013)... HealthSmart continues to grow through strategic acquisitions ... the hiring of new talent in several areas, including ... that Dawn Powell has joined the organization effective April ... Account Management in the Central Region and is based ... extensive client management, employee benefits, and product development experience, ...
(Date:5/21/2013)... 21 May 2013, Paris, France: One-year results from SOURCE ... valve implantation (TAVI) registries to-date reported today at ... practice, with high rates of device success for all ... SOURCE XT Post-Approval Study followed up 2688 consecutively enrolled ... Sapien XT heart valve at 93 centres in 17 ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
Breaking Medicine News(10 mins):Health News:Glaucoma drug can cause droopy eyelids 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4
... Long Island Patient Information eXchange (LIPIX) went live with ... accessing LIPIX online systems. LIPIX realizes the value ... through its HIE, but also understands that it is ... that the information will be protected. "As more ...
... But weight training can boost strength in other ways, researchers ... did not build muscle mass in octogenarian women but still ... conducted by Ball State University in Indiana finds. , ... three times a week for three months on a machine ...
... to Self-Report Suspected MeaslesHARRISBURG, Pa., April 3 The Pennsylvania ... Department and UPMC,s Children,s Hospital of Pittsburgh today confirmed they ... Hospital. Exposures to measles may have occurred in the Children,s ... , March 10, at ...
... /PRNewswire-FirstCall/ - The Westaim Corporation today announced that ... to maximize the value of the Company,s strong ... strategy, Westaim has entered into a management services ... an affiliate of Goodwood Inc., to manage the ...
... 3 eDiets.com, Inc. (Nasdaq: DIET ... healthy lifestyle solutions, today announced that it received a notice ... of the Company,s listed securities has fallen below $35 million, ... Market, in compliance with NASDAQ Marketplace Rule 4310(c)(3)(B). The ...
... the toxin in leg bones are tied to poorer scores on ... higher levels of environmental lead earlier in the life span may ... a new study finds. , The Harvard study shows that women ... blood (indicating a recent exposure to the metal) or bones (an ...
Cached Medicine News:Health News:LIPIX Protects Access to Electronic Health Information With the Anakam Identity Suite(R) 2Health News:LIPIX Protects Access to Electronic Health Information With the Anakam Identity Suite(R) 3Health News:Muscle Mass Won't Grow in Women Over 80 2Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 2Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 3Health News:Westaim enters into Management Services Agreement 2Health News:eDiets.com(R) Receives NASDAQ Notice Regarding Market Value of Listed Securities 2Health News:eDiets.com(R) Receives NASDAQ Notice Regarding Market Value of Listed Securities 3Health News:Accumulated Lead May Affect Older Women's Brains 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: